SCHEMBL22490159

SCHEMBL22490159

Cc1ccc(C(=O)Nc2ccn(COCC[Si](C)(C)C)n2)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.44
RAB9A P51151 8/20 0.42
NPC1 O15118 7/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
HPGD P15428 2/20 0.41
CYP2C9 P11712 1/20 0.41
GCK P35557 1/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
ALDH1A1 P00352 5/20 0.41
MAPK1 P28482 2/20 0.40
LMNA P02545 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27076442 0.80 CACNA1G (0.40) RAB9ANPC1SMN1; SMN2CYP2C9GCK
SCHEMBL22490239 0.75 NPC1 (0.66) MTORRAB9ANPC1SMN1; SMN2HPGD
SCHEMBL23213224 0.71 CACNA1G (0.40) RAB9ANPC1SMN1; SMN2HPGDMAPT
SCHEMBL20744490 0.68 DGAT1 (0.40) NPC1SMN1; SMN2
SCHEMBL3531426 0.67 KMT2A (0.32) RAB9ANPC1SMN1; SMN2CYP2C9GCK
SCHEMBL15300965 0.67 DGAT1 (0.37)
SCHEMBL6840285 0.67 LDHB (0.31) NPC1CYP2C9GCKMAPT
SCHEMBL22468550 0.67 SMN1; SMN2 (0.58) MTORRAB9ANPC1SMN1; SMN2HPGD
SCHEMBL29477007 0.67 MTOR (0.56) MTORRAB9ANPC1SMN1; SMN2HPGD
SCHEMBL19926085 0.67 KMT2A (0.49) RAB9ANPC1SMN1; SMN2CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020198053-A1 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-10-01 WO disclosed